Zalicus completed Phase 1 pharmacokinetic and safety studies and has picked the optimal formulation to move into further clinical development, the company said. The selected formulation demonstrated a six-fold improvement in Z160's bioavailability compared to the previously studied formulation of Z160.
"The lack of adequate pain control in patients with chronic neuropathic pain represents a significant unmet need and important opportunity for novel agents with improved tolerability, enhanced efficacy, and better long-term safety profiles," said Mark Corrigan, Zalicus president and CEO.
Related Articles on Pain Management:Pre-Op Educational Video May Reduce Patient Pain
Ameritex Launches Tool for Chronic Pain Assessment
Kentucky Physicians Express Concern Over New 'Pill Mill' Law